The Medicines Co. to acquire Tenaxis for $58M The Medicines Company and Tenaxis Medical announced an agreement for The Medicines Company to acquire Tenaxis. Tenaxis's sole product, which mechanically seals both human tissue and artificial grafts is approved, but not launched in the US -- having received U.S. PMA approval from the FDA in March 2013 as a vascular sealant. The product is also approved with a European CE Mark as a surgical sealant applicable to cardiovascular, general, urological, and thoracic surgery. Under the terms of the agreement, The Medicines Company will pay $58M upfront on closing of the deal. The Medicines Company will also pay milestone payments of up to $112M contingent upon achieving certain commercial and -- in pursuit of even broader indications -- regulatory approval milestones.